MTC is reported to show IC50 = 0.15 μM for the dissolution of PHFs isolated from AD brain, while its EC50 to cause 50% inhibitions of microtubule assembly and tau expression level are 50 μM and 10 μM respectively [109], leading to the benign conclusion that using MTC-based TAIs as AD therapeutics is unlikely to disrupt normal tau functionality. Here, MAPT is linked to Alzheimer disease.